Jonathon Whitton

Company: Decibel Therapeutics

Job title: Vice President of Clinical Research

Seminars:

DB-OTO, Gene Therapy Product Designed to Provide Hearing to Individuals with Otoferlin Mutations 1:45 pm

• DB-OTO is an AAV-based dual-vector investigational product candidate designed to restore hearing to individuals with profound, congenital hearing loss due to otoferlin deficiency • DB-OTO utilizes a proprietary, cell-selective promoter to express otoferlin in hair cells • Pre-clinical studies have demonstrated restoration of hearing in a mouse model after administration of DB-OTORead more

day: Post Conference Day